Panel Discussion: Translating Structural Insights into Better Drug Candidates by Connecting Structure, Design & Developability to Accelerate Candidate Progression

2:30 pm - Thursday 4th February 2027

Structural biology can provide powerful insights into molecular recognition and binding, but its greatest value comes when those insights are generated early enough and applied broadly enough to influence drug design. As discovery teams increasingly seek to use structures to improve not only binding but also stability, expression, and developability, the challenge is creating workflows that translate structural information into better molecules. Join structural biologists, medicinal chemists, computational scientists, and drug discovery leaders as they discuss how to maximise the impact of SBDD on candidate progression by:

Bringing structural information earlier into discovery, examining how delays between chemistry and structural data can limit decision making and how teams can prioritize structures that have the greatest potential to influence molecular design
Translating structural insights into broader molecular optimization, exploring how structural information can be used to improve affinity and binding while also informing stability, expression, and developability
Connecting structure-guided design with candidate progression, discussing how structural and computational insights can be incorporated into hit prioritization, lead optimization, and candidate selection to deliver better molecules more efficiently